Istodax® (romidepsin) – Indication withdrawal
August 2, 2021 - Bristol-Myers Squibb (BMS) announced that the company plans to voluntarily withdraw the indication for Istodax (romidepsin) as monotherapy for the treatment of peripheral T-cell lymphoma (PTCL) in adult patients who have received at least one prior therapy.
Top